EUVIMEDEUVIMED entdecken
Crossref

Anticancer 1,3-thiazole Derivatives: In Vitro Evaluation and in Silico Tubulin/Lipoxygenase Inhibition

Yasin SarveAhrabi, Saina Aqa Abedi, Mastaneh Ahmadirad, Nakisa Zarrabi Ahrabi

Pharmaceutical and Biomedical Research · 01.03.2026 · 12 (2) · 87-98

DOI: 10.32598/pbr.12.1.1379.1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical and Biomedical Research, erschienen am 01.03.2026. Verfasst von Yasin SarveAhrabi und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In Vitro Evaluation and in Silico Tubulin/Lipoxygenase InhibitionBackground: Addressing cancer treatment and drug resistance is critical because cancer remains a leading cause of death worldwide.Targeting key enzymes, such as tubulin and lipoxygenase, may yield new strategies to impede tumor growth and enhance treatment efficacy.

Objectives

This study aimed to evaluate the anticancer effects of 1,3-thiazole derivatives on A549 and HT-29 cancer cell lines and investigate their ability to inhibit tubulin and lipoxygenase enzymes.

Methods

Ethyl and methyl derivatives with a central 1,3-thiazole core were synthesized in one step.A549 and HT-29 cells were cultured in RPMI 1640 medium.The cytotoxic effects of the derivatives were assessed by treating the cells with varying concentrations for 24, 48, and 72 hours, followed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays.Molecular docking using AutoDock Vina software, version 1.1.2was performed to evaluate the derivatives' inhibitory effects on tubulin and lipoxygenase.

Results

Compound A demonstrated significant anticancer activity against A549 cells at 500 µg/mL.Compound B also inhibited 50% of cancer cells at 1000 µg/mL.In the HT-29 cell line, compound A reduced cell viability by 50% at 500 µg/mL, while compound B showed stronger effects at the same concentration.Ligand A exhibited notable inhibitory potential against tubulin, whereas ligand B had significant inhibitory effects against tubulin and lipoxygenase. Conclusion:The ethyl substituent of the 1,3-thiazole core shows promise as an anticancer agent against A549, while the methyl substituent is effective against HT-29.Both derivatives can inhibit tubulin function.

Zitieren

APA

SarveAhrabi, Y., Abedi, S. A., Ahmadirad, M., & Ahrabi, N. Z. (2026). Anticancer 1,3-thiazole Derivatives: In Vitro Evaluation and in Silico Tubulin/Lipoxygenase Inhibition. Pharmaceutical and Biomedical Research, 12(2), 87-98. https://doi.org/10.32598/pbr.12.1.1379.1

Vancouver

SarveAhrabi Y, Abedi SA, Ahmadirad M, Ahrabi NZ. Anticancer 1,3-thiazole Derivatives: In Vitro Evaluation and in Silico Tubulin/Lipoxygenase Inhibition. Pharmaceutical and Biomedical Research. 2026;12(2):87-98. doi:10.32598/pbr.12.1.1379.1

BibTeX
@article{SarveAhrabi2026,
  author = {SarveAhrabi, Yasin and Abedi, Saina Aqa and Ahmadirad, Mastaneh and Ahrabi, Nakisa Zarrabi},
  title = {Anticancer 1,3-thiazole Derivatives: In Vitro Evaluation and in Silico Tubulin/Lipoxygenase Inhibition},
  journal = {Pharmaceutical and Biomedical Research},
  year = {2026},
  volume = {12},
  number = {2},
  pages = {87--98},
  doi = {10.32598/pbr.12.1.1379.1}
}
Kostenlos starten →